Technology
Overview
)
Technology
Overview
Antibody Drug Conjugates (ADCs) combine the selectivity of monoclonal antibodies (mAbs) with the high efficacy of small molecules to offer innovative treatment possibilities to patients. To maximize their potential benefit, each ADC is tailormade and must address diverse factors impacting their properties. This includes choice of Antibody, Payload, Drug-Antibody-Ratio (DAR), conjugation site and homogeneity of the generated conjugate.
Our technologies enable us to find for each target antigen the right combination of these properties, thereby unlocking potential novel therapies.
)
01 SITE SPECIFIC CONJUGATION
Enzymatic conjugation with sortaseA enzyme (Transpeptidase enzyme)
SMAC-technologyTM = sortase (-enzyme) mediated antibody conjugation
02 PNU ANTHRACYCLINE PAYLOAD
Highly potent anthracycline-based DNA damaging intercalating toxin (pico molar potency)
03 ANTIBODY DISCOVERY
Novel binders against any novel target
Mammalian Ab library display system
04 IADC
Immune-Oncology function of anthracyclines well documented. Best-in-class activators of DCs (usually serve as positive controls) and strongly stimulating adaptive, cellular immunity